Previous 10 | Next 10 |
Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidance Combination trial of AMT-101 with anti-TNF α in moderate-to-severe ulcerative colitis (UC) patients in the fourth quarter of 2021; Monotherapy tri...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Can...
Applied Molecular Transport (AMTI) announces additional Phase 1b data for oral AMT-101 in ulcerative colitis ((UC)) patients.The Phase 1b multiple ascending dose trial evaluated safety and was a randomized, placebo-controlled 3:1, double-blind trial that included 16 patients with active ...
Once daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology Key findings support oral AMT-101 actively exerts immunomodulatory effect resulting in local and systemic be...
Applied Molecular Transport ([[AMTI]] -4.8%) stock drops 4.5% as director Helen Susan Kim sells 200,000 shares.Shares were priced between $43.3 to $46.47, worth approximately $8.7M.Director holds 600,000 shares post transaction.The stock has a current market cap of $1.75B.Stock has&...
Gainers: Virpax Pharmaceuticals (VRPX) +16%, Anavex Life Sciences AVXL +15%, MediciNova MNOV +14%, Aytu Biopharma (AYTU) +14%, Applied Molecular Transport (AMTI) +8%.Losers: Aptevo Therapeutics (APVO) -18%, Intec Pharma (NTEC) -16%, Conformis ...
SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the...
SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the ...
Applied Molecular Transport (AMTI): Q1 GAAP EPS of -$0.58 beats by $0.17.Cash, cash equivalents, and investments were $108.3 million.Press Release For further details see: Applied Molecular Transport EPS beats by $0.17
Enrollment ongoing in each of oral AMT-101’s four Phase 2 trials On track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials, being conducted in multiple ulcerative colitis populations and rheumatoid arthritis, beginning in the second half of 202...
News, Short Squeeze, Breakout and More Instantly...
Applied Molecular Transport Inc. Company Name:
AMTI Stock Symbol:
NASDAQ Market:
Applied Molecular Transport Inc. Website:
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceut...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...